Market statusData NSENot investment advice
DISHMAN CARBO AMCIS

DISHMAN CARBO AMCIS Latest Share Price (DCAL)

NSE: DCALBSE 540701HealthcarePharmaceuticalsimdcal.com
TechnicalsTV Chart
174.38
2.61−1.47%
Overall Score43/100
Day range173
₹174.38
179
52-week129
₹174.38
322
Above low+35.7%
Below high45.8%
Range position24%
Open178.50
Prev Close176.99
Bid174.36100
Ask174.41100

TODAY IN ONE LINE

DCAL fell 1.5% on light volume, lagging Nifty's 0.1% move.

With a market cap of ₹2,723.32 Cr., it trades at a P/E of 172.04. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume122.9K73%vs 20D avg
Market Cap₹2,723.32 Cr.
PromoterNot applicable
Face Value₹2
Fwd P/E13.85
PEG0.01
EV/EBITDA13.69
P/S0.96
ROA1.29%
Beta1.69
Div Payout
THE STOCK SCORE
Overall Score43/100
Updated 05 Sept

How good is this company?

Overall performance across 5 key dimensions.

Each card tappable → shows formula + inputs
FLAGS & NEWS

DISHMAN CARBO AMCIS flags & news 

Key strengths, potential risks, and recent updates.

1 green flag🚩 4 red flags

Green Flags

  • Zero Pledge RiskNo recent active promoter pledging found

Red Flags

  • Earnings DeclineEPS (TTM) has contracted by 49.5% YoY
  • Sales ContractionQuarterly sales dropped 91.6% YoY
  • Poor Capital ReturnsLow ROE of 1.5%
  • Rising Receivables vs SalesReceivables grew 37.3% outpacing sales growth of 3.7%

Latest DISHMAN CARBO AMCIS News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

05 SEPT 2026
corporate
Shareholders meeting - Dishman Carbogen Amcis Limited has informed the Exchange regarding Notice of Annual General Meeting ...
View PDF
02 SEPT 2026
corporate
Copy of Newspaper Publication - Dishman Carbogen Amcis Limited has informed the Exchange about Copy of Newspaper Publication for int...
View PDF
31 AUG 2026
corporate
Updates - Dishman Carbogen Amcis Limited has informed the Exchange regarding 'Intimation regarding date of 19t...
View PDF
🔒Prime: full history + alerts on this stock
Valuation

DISHMAN CARBO AMCIS valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for DISHMAN CARBO AMCIS, framed against the sector median so the premium or discount is obvious at a glance.

DISHMAN CARBO AMCIS trades at a P/E of 172.04× and P/B of 0.42×.

Key MetricsMarket + reported · 04 Sept 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
₹2,723.32 Cr.
P/E Ratio
172.04
P/B Ratio
0.42
EPS
₹-1.53
Profitability

Profitability

ROE
1.46%
ROCE
1.52%
Net Margin
2.51%
Op Margin
9.52%
Growth

Growth

EPS YoY
-49.5%
Revenue YoY
18.9%
Qtr Sales
-91.58%
Qtr Profit
58.69%
Financial Health

Financial Health

Debt / Equity
0.42
Book Value
₹425.87
Div Yield
Promoter Holding
Not applicable
Technicals

DISHMAN CARBO AMCIS technical analysis: indicators, pivots and CPR.

Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for DISHMAN CARBO AMCIS — derived from the latest tape, not yesterday's close.

DISHMAN CARBO AMCIS last traded at ₹174.38 with an intraday range of ₹173.2–₹178.5 — latest indicator, pivot and CPR signals below.

Last updated: 6 September 2026, 4:08 pm IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Last: ₹174.38
LevelPrice (₹)Distance% Δ
R4188.12+13.74+7.88%
R3182.82+8.44+4.84%
R2180.66+6.28+3.60%
R1177.52+3.14+1.80%
PIVOT175.360.980.56%
CURRENT174.38
S1172.22-2.16-1.24%
S2170.06-4.32-2.48%
S3166.92-7.46-4.28%
S4161.62-12.76-7.32%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 174.87P: 175.36TC: 175.85
R1
R2
R3
R4
indicator
LTP: 174.38
PDH: 179.90
PDL: 175.40
● Market Sentiment

DCAL is trading Below CPR, indicating Bearishness

● CPR Width

CPR is Wider, suggesting unlikely for trending moves

● Opening Range

Day's range: 176.03178.5

● Price Position

Trading Below opening range, showing Bearishness

Financials

DISHMAN CARBO AMCIS financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for DISHMAN CARBO AMCIS — consolidated or standalone — with margins, YoY growth and key ratios inline.

DISHMAN CARBO AMCIS reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,723.32 Cr. and reported EPS of ₹-1.53.

iTap any row for a plain-English meaningChange vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
Mobile view
Latest vs previous year
MetricMar 2025Mar 2026
Revenue from Operations2,712
2,932
8.1%
Sales Growth YoY %Derived3.66%
8.13%
Other Income22
56
158.0%
Total Income2,733
2,988
9.3%
502
409
18.5%
Gross ProfitDerived2,210
2,523
14.2%
Gross Margin %Derived81.50%
86.06%
1,741
1,957
12.4%
EBITDA (Operating Profit)Derived469
566
20.6%
OPM %Derived17.29%
19.29%
435
509
17.0%
Profit Before Tax (PBT)19
105
443.2%
16
7
53.6%
Effective Tax %Derived83.22%
7.10%
Total Profit for Period3
97
2907.7%
Net Profit (Owner's PAT)Derived3
97
2907.7%
Net Profit Margin %Derived0.12%
3.32%
PAT Growth YoY %Derived102.11%
2,907.72%
Earnings Per Share (EPS ₹)0.21
6.22
2861.9%
Diluted Shares Outstanding (Cr)16
16
0.0%
Other Comprehensive Income (Net of Tax)201
748
272.5%
Total Expenses (incl. D&A & Interest)2,714
2,883
6.2%
Material Cost % of RevenueDerived21.87%
16.64%
Employee Cost % of RevenueDerived47.71%
49.35%
Other Cost % of RevenueDerived16.50%
17.41%
Interest Coverage (x)Derived1.10x
1.30x
Sales CAGR · 3Y
+6.7%
Sales CAGR · 5Y
+8.9%
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

DISHMAN CARBO AMCIS segment analysis : revenue and profit mix.

Disclosed business segments at DISHMAN CARBO AMCIS with their share of revenue and profit, switchable between consolidated and standalone reporting.

DISHMAN CARBO AMCIS discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for DISHMAN CARBO AMCIS.

Our AI distills the core fundamental drivers supporting DISHMAN CARBO AMCIS, the risks that threaten it, and the quantitative conditions that could weaken the thesis.

DISHMAN CARBO AMCIS's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.

bull case

What you're getting.

  • TTM revenue growth 18.9% YoY outpaces pharmaceutical sector median, signaling strong CRAMS demand recovery.

  • Operating cash flow ₹295.23 Cr latest quarter positive despite negative PAT, demonstrating cash generation resilience.

  • Operating margin 7.74% TTM maintained despite competitive pressures, reflecting reasonable cost control discipline.

  • FII holdings increased from 5.85% to 8.07%, signaling growing international investor confidence in turnaround potential.

  • Diversified product portfolio across APIs, specialty chemicals, and sterile injectables reduces client concentration risk.

bear case

Key Risks.

  • Latest quarterly EPS declined 49.5% YoY, indicating severe earnings volatility and profitability stress.

  • ROE 1.46% and ROCE 1.52% far below sector averages, reflecting critically poor capital efficiency.

  • Three consecutive loss years (FY24–FY26) with cumulative PAT ₹-123.68 Cr raise solvency sustainability questions.

  • Net profit margin compressed to 2.51% TTM from 3.32% annual, signaling margin erosion amid cost pressures.

  • Current ratio 0.79x below 1.0 threshold; liquidity stress with short-term debt ₹506.76 Cr versus cash ₹15.93 Cr.

flip conditions

Flip Conditions.

  • Valuation risk. a P/E above 224 would leave less room for earnings disappointment.

  • Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.

  • Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.

  • Return-quality risk. ROE below 8% would indicate weaker capital compounding.

Shareholding

DISHMAN CARBO AMCIS shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in DISHMAN CARBO AMCIS — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

AnnualJun 2026

DII2.07%0.44%
Public31.75%0.15%
FII6.86%0.59%
Promoters59.32%

Ownership Distribution

Domestic Institutions
2.07%
Retail & Public
31.75%
Foreign Institutions
6.86%
Promoters
59.32%

Category Trends

Foreign Institutions Breakdown
Total Holding: 6.86%
Net Change: -0.59%
Category Total6.86%
Total Holding6.86%
Net Change-0.59%
Not Fully Disclosed

⚠️Partial Disclosure Notice

Individual institutions below total 4.47%, but category aggregate is 6.86%. Some institutions may not be disclosed by the company as per regulatory requirements.

Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
2.28%
0.00%
0.00%
Jun 2026
Hbm Healthcare Investments (Cayman) Ltd
2.19%
0.00%
0.00%
Jun 2026
HBM Healthcare Investment(Cayman) Ltd.
0.00%
0.00%
0.00%
Jun 2026
LSV EMERGING MARKETS EQUITY FUND LP
0.00%
0.00%
0.00%
Jun 2026
Government Pension Fund Global
0.00%
0.00%
0.00%
Jun 2026
Peers

DISHMAN CARBO AMCIS peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — DISHMAN CARBO AMCIS is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
SUN PHARMACEUTICAL IND L
₹4.56 Lakh Cr
Best Profit Growth
SENORES PHARMACEUTICALS L
2856.31 %
Highest Dividend Yield
SANOFI INDIA
3.96 %

Peer Comparison

Company Name
09 · Chart Patterns

DISHMAN CARBO AMCIS chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for DISHMAN CARBO AMCIS — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

Delivery Conviction

DISHMAN CARBO AMCIS delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for DISHMAN CARBO AMCIS over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in DISHMAN CARBO AMCIS stood at 60.3% of traded volume, against a 20-day average of 51.2%.

Avg Delivery (20D)51.2%+9.1 ppt latest vs avg
Highest Delivery72.9%on 28 Aug
Avg Volume (20D)4.48 L20-day run-rate
Conviction Trend↑ Strengthening+9.1 ppt latest read
Volume & Delivery · last 20 sessions
Exchange Filings & Investor Updates

DISHMAN CARBO AMCIS announcements: results, concalls, ratings, M&A.

Filings DISHMAN CARBO AMCIS sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

DISHMAN CARBO AMCIS files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 128 documents below.

  1. 05 Sept 2026Shareholders meetingView PDF

    Shareholders meeting

    Dishman Carbogen Amcis Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026

  2. 02 Sept 2026Copy of Newspaper PublicationView PDF

    Copy of Newspaper Publication

    Dishman Carbogen Amcis Limited has informed the Exchange about Copy of Newspaper Publication for intimation regarding 19th AGM to be held through…

  3. 31 Aug 2026UpdatesView PDF

    Updates

    Dishman Carbogen Amcis Limited has informed the Exchange regarding 'Intimation regarding date of 19th Annual General Meeting'.

  4. 29 Aug 2026CessationView PDF

    Cessation

    Dishman Carbogen Amcis Limited has informed the Exchange regarding Cessation of Mr Deepak Ram Chandra Mittal as Other of the company w.e.f. August…

  5. 21 Aug 2026Analysts/Institutional Investor Meet/Con. Call UpdatesView PDF

    Analysts/Institutional Investor Meet/Con. Call Updates

    Dishman Carbogen Amcis Limited has informed the Exchange about Transcript

Corporate Actions

DISHMAN CARBO AMCIS dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue DISHMAN CARBO AMCIS has declared, sequenced by announce and record date.

DISHMAN CARBO AMCIS corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

About the Company

About DISHMAN CARBO AMCIS: business, sector, key facts.

What DISHMAN CARBO AMCIS does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

DISHMAN CARBO AMCIS operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: DCAL, BSE: 540701.

DCAL
Healthcare

DISHMAN CARBO AMCIS

NSE · DCAL·BSE · 540701·imdcal.com

Dishman Carbogen Amcis Limited (DCAL) is a global contract research and manufacturing services (CRAMS) provider catering to the pharmaceutical, healthcare, and biotechnology sectors. Their core business revolves around offering comprehensive services throughout the drug development and manufacturing lifecycle, from research and development to the production of finished products. This broad scope allows them to partner with clients across various stages of drug development and commercialization.

The company's operations are primarily structured around two segments: Contract Research and Manufacturing Services and Marketable Molecules. The CRAMS segment focuses on providing customized solutions for clients' research and manufacturing needs, encompassing a wide range of services tailored to specific client requirements. This includes everything from the initial stages of drug discovery and development to large-scale manufacturing of pharmaceutical products.

The Marketable Molecules segment involves the manufacturing and supply of various pharmaceutical and related products. This segment includes a diverse portfolio of offerings, ranging from bulk drugs and active pharmaceutical ingredients (APIs), including both general and highly potent APIs, to specialty chemicals used in pharmaceutical and cosmetic applications. Specific examples of their manufactured products include intermediates, fine chemicals, phosphoranes, solid quaternary ammonium compounds, and Wittig reagents.

Beyond these core offerings, DCAL also produces a range of other products. This diversification further strengthens their market position and demonstrates their commitment to providing a wide array of solutions to their clients. Their product portfolio extends to vitamin D products and analogues, personal care items like hand and body wash, sanitizers, and antiseptics, and even phase transfer catalysts, soft gel capsules, disinfectant formulations, cholesterol-related products, lanolin-related products, and liquid and lyophilized sterile injectables.

Established in 1983 and headquartered in Ahmedabad, India, DCAL is a subsidiary of Adimans Technologies LLP. Their extensive product range and comprehensive service offerings position them as a significant player in the global pharmaceutical and healthcare industries, providing a valuable link in the chain from drug discovery to market delivery.

company facts
Employees
SectorHealthcare
HeadquartersAhmedabad, India
Market Cap₹2,723.32 Cr.
Listed OnNSE
leadership18 on record
Dr. Alan Fischer Ph.D.
Chief Technology Officer of CARBOGEN AMCIS
Dr. Himani S. Dhotre
CEO of Projects & Operations
Dr. Martin Schneider Ph.D.
Chief Quality & Compliance Officer of CARBOGEN AMCIS
Lucie Framinet
Marketing Manager
Mr. Arpit Janmejay Vyas
Global MD & Director
Mr. Arpit Vyas
Global Managing Director, Executive Director
Mr. Dharmesh Desai
GM of Secretarial & Legal
Mr. Dhaval Shah
Non-Executive Non-Independent Director
Mr. Harshil Dalal
Global Chief Financial Officer
Mr. Harshil R. Dalal
Global Chief Financial Officer
Mr. Hemantkumar Jayantiprasad Bhatt
Non-Executive Independent Director
Mr. Kulin Shah
Independent Director
§ ∞ · Plainly Answered

Questions investors ask about DISHMAN CARBO AMCIS (DCAL).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of DISHMAN CARBO AMCIS (DCAL)?

The current share price of DISHMAN CARBO AMCIS (DCAL) is ₹174.38. Today, the stock has declined by ₹2.61 (1.47%), trading in a range of ₹173.20 to ₹178.50. The stock opened at ₹178.50 with a trading volume of 1,22,894 shares.

02Is DISHMAN CARBO AMCIS stock a good investment for long-term?

DISHMAN CARBO AMCIS can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,723.32 Cr., P/E ratio of 172.04, ROE of 1.46%, and ROCE of 1.52%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of DISHMAN CARBO AMCIS stock?

The 52-week high price of DISHMAN CARBO AMCIS (DCAL) is ₹321.95, while the 52-week low is ₹128.50. Currently trading at ₹174.38, the stock is 35.7% above its 52-week low and 45.84% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy DISHMAN CARBO AMCIS stock at the current price?

Whether to buy DISHMAN CARBO AMCIS stock at ₹174.38 depends on multiple factors. The stock is currently trading with a P/E ratio of 172.04 and P/B ratio of 0.42. Today's performance shows a loss of 1.47%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of DISHMAN CARBO AMCIS and when is the next dividend?

DISHMAN CARBO AMCIS offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹174.38, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of DISHMAN CARBO AMCIS?

DISHMAN CARBO AMCIS's key financial metrics include: P/E Ratio: 172.04, P/B Ratio: 0.42, ROE: 1.46%, ROCE: 1.52%, Dividend Yield: 0%, EPS: ₹-1.53, Book Value: ₹425.87, and Debt-to-Equity: 0.42. The company's market cap stands at ₹2,723.32 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is DISHMAN CARBO AMCIS stock performing today in the market?

DISHMAN CARBO AMCIS stock opened at ₹178.50 and is currently trading at ₹174.38, showing a decline of ₹2.61 (1.47%). The intraday high is ₹178.50 and low is ₹173.20. The trading volume stands at 1,22,894 shares, indicating moderate market participation today.

08What is the P/E ratio of DISHMAN CARBO AMCIS and what does it indicate?

DISHMAN CARBO AMCIS has a Price-to-Earnings (P/E) ratio of 172.04, which means investors are willing to pay 172.04 for every ₹1 of earnings. With an EPS of ₹-1.53, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about DISHMAN CARBO AMCIS (DCAL) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.